We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Suppression of Tumor Growth Linked to Actions of the Ubiquitin System

By LabMedica International staff writers
Posted on 21 Apr 2015
Print article
Image: Senior author Dr. Aaron Ciechanover shared the 2004 Nobel Prize in chemistry for his work on the ubiquitin system (Photo courtesy of the Technion-Israel Institute of Technology).
Image: Senior author Dr. Aaron Ciechanover shared the 2004 Nobel Prize in chemistry for his work on the ubiquitin system (Photo courtesy of the Technion-Israel Institute of Technology).
Image: The dramatic effect of these proteins on cancer growth: above the two tumors in the foreground (the control group) are tumors that express high levels of the proteins KPC1 and p50 (Photo courtesy of the Technion-Israel Institute of Technology).
Image: The dramatic effect of these proteins on cancer growth: above the two tumors in the foreground (the control group) are tumors that express high levels of the proteins KPC1 and p50 (Photo courtesy of the Technion-Israel Institute of Technology).
Cancer researchers working with mouse xenograft and human cancer cell cultures have identified components of the ubiquitin system that are linked to certain cellular processes, which act to suppress malignant growth and protect healthy tissues.

Ubiquitin is a small protein that exists in all eukaryotic cells. It performs myriad functions through conjugation to a large range of target proteins. The ubiquitin protein itself consists of 76 amino acids and has a molecular mass of about 8.5 kDa. Key features include its C-terminal tail and the seven lysine residues. It is highly conserved among eukaryotic species with human and yeast ubiquitin sharing 96% sequence identity. Ubiquitination is an enzymatic, protein post-translational modification (PTM) process in which the carboxylic acid of the terminal glycine from the di-glycine motif in the activated ubiquitin forms an amide bond to the epsilon amine of the lysine in the modified protein.

Investigators at the Technion-Israel Institute of Technology (Haifa, Israel) have focused on the protein KPC1 (Kip1 ubiquitylation-promoting complex 1), the catalytic subunit of the ubiquitin ligase KPC, and in particular on its relation to p105, a long precursor of the key cell regulator NF-kappaB.

The NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) family of transcription factors comprises five structurally related proteins that form homo- and hetero-dimers through their highly conserved DNA binding/dimerization Rel homology domain. Binding of NF-kappaB to IkappaB proteins maintains NF-kappaB in an inactive state. Activation of NF-kappaB in normal cells is inducible and is a tightly controlled event. Upon stimulation, IkappaBs are phosphorylated by the IkappaB kinase (IKK) complex (consisting of IKK1, IKK2, and NEMO proteins). IkappaB phosphorylation leads to its rapid proteolysis, thereby allowing NF-kappaB to function as a transcription factor.

The investigators reported in the April 9, 2015, issue of the journal CELL that KPC1 ubiquitinated p105, resulting in the shortened protein p50. Working with mouse xenograft and human cancer cell cultures, they showed that high levels of KPC1 and p50 correlated with inhibition of tumor growth. Furthermore, KPC1 and p50 levels were lower in tumors than in normal tissue.

While these findings are of considerable importance in understanding molecular pathways that suppress cancer formation, senior author Nobel prize laureate Dr. Aaron Ciechanover, professor of biochemistry at the Technion-Israel Institute of Technology said, "Many more years are required to establish the research and gain a solid understanding of the mechanisms behind the suppression of the tumors. The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple."

Related Links:

Technion-Israel Institute of Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.